A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours

British Journal of Cancer

Volumn 112, Issue 1, 2015, Pages 24-31

  Wilky, B A ^a   Rudek, M A ^a   Ahmed, S ^a   Laheru, D A ^a   Cosgrove, D ^a   Donehower, R C ^a   Nelkin, B ^a   Ball, D ^a   Doyle, L A ^b   Chen, H ^b   Ye, X ^a   Bigley, G ^c   Womack, C ^c   Azad, N S ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c ASTRAZENECA   (United Kingdom)

Author keywords

BRAF; clinical trial; IGF; IGF 1R; MEK

Indexed keywords

CIXUTUMUMAB; MITOGEN ACTIVATED PROTEIN KINASE; S6 KINASE; SELUMETINIB; SOMATOMEDIN; TRIACYLGLYCEROL LIPASE; ANTI-IGF-1R ANTIBODY A12; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MONOCLONAL ANTIBODY; SOMATOMEDIN C RECEPTOR;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BASAL CELL CARCINOMA; BILIARY TRACT TUMOR; BLEEDING; BURNING SENSATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; COLORECTAL CANCER; CONFUSION; CONSTIPATION; COUGHING; DIARRHEA; DIZZINESS; DOSE CALCULATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME REPRESSION; EYE DISEASE; FATIGUE; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; LEUKOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MUSCLE FATIGUE; MYALGIA; NAUSEA AND VOMITING; NEUTROPENIA; OPEN STUDY; PANCREAS TUMOR; PANCREATITIS; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PROSTATE TUMOR; PROTEIN EXPRESSION; SARCOMA; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN DISEASE; SOLID TUMOR; THROMBOSIS; THYROID CARCINOMA; TINNITUS; TONGUE CARCINOMA; TREATMENT RESPONSE; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; TUMOR BIOPSY; UTERINE CERVIX TUMOR; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE FREE SURVIVAL; METABOLISM; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MAP KINASE KINASE KINASES; MIDDLE AGED; NEOPLASMS; RECEPTOR, IGF TYPE 1; TREATMENT OUTCOME;

EID: 84920641580     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.515     Document Type: Article

References (36)

1. Adjei A, Cohen R, Franklin W, Morris C, Wilson D, Molina J, Hanson L, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt S (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26: 2139-2146.
2. Banerji U, Camidge D, Verheul H, Agarwal R, Sarker D, Kaye S, Desar I, Timmer-Bonte J, Eckhardt S, Lewis K, Brown K, Cantarini M, Morris C, George S, Smith P, Herpen CV (2010) The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res 16: 1613-1623.
3. Baserga R (1999) The IGF-1 receptor in cancer research. Exp Cell Res 253: 1-6.
4. Bertrand F, Steelman L, Chappell W, Abrams S, Shelton J, White E, Ludwig D, Mccubrey J (2006) Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1Rmediated growth in hematopoietic cells. Leukemia 20: 1254-1260.
5. Britten C (2013) PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types. Cancer Chemother Pharmacol 71: 1395-1409.
6. Buck E, Eyzaguirre A, Rosenfeld-Franklin M, Thomson S, Mulvihill M, Barr S, Brown E, O'connor M, Yao Y, Pachter J, Miglarese M, Epstein D, Iwata K, Haley J, Gibson N, Ji Q (2008) Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors. Cancer Res 68: 8322-8332.
7. Chang L, Karin M (2001) Mammalian MAP kinase signalling cascades. Nature 410: 37-40.
8. Chen R, Sweet-Cordero E (2013) Two is better than one: combining igf1r and mek blockade as a promising novel treatment strategy against KRASmutant lung cancer. Cancer Discov 3: 491-493.
9. Flanigan S, Pitts T, Newton T, Kulikowski G, Tan A, Mcmanus M, Spreafico A, Kachaeva M, Selby H, Tentler J, Eckhardt S, Leong S (2013) Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res 19: 6219-6229.
10. Gabrielsson J, Weiner D (2012) Non-compartmental analysis. Methods Mol Biol 929: 377-389.
11. Higano C, Yu Y, Whiting S (2007) A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monocolonal antibody, in patients with advanced solid tumors. J Clin Oncol 25(suppl): abstract 3505.
12. Imclone Systems Inc (2006) Anti-insulin-like growth factor-I receptor (IGF-1R) monoclonal antibody investigator's brochure.
13. Ji Q-S (2007) Preclinical Characterization of OSI-906: A Novel IGF-1R Inhibitor in Clinical Trials (Abstract #C192). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics San Francisco, CA, USA.
14. Jin M, Buck E, Mulvihill M (2013) Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives. Oncology Reviews 7: e3.
15. Khokhlatchev A, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb M (1998) Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell 93: 605-615.
16. Leijen S, Soetekouw P, Evans TJ, Nicolson M, Schellens J, Learoyd M, Grinsted L, Zazulina V, Pwint T, Middleton M (2011) A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors. Cancer Chemother Pharmacol 68: 1619-1628.
17. Liu D, Xing M (2008) Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid 18: 853-864.
18. Mckian K, Haluska P (2009) Cixutumumab. Expert Opin Investig Drugs 18: 1025-1033.
19. Molina-Arcas M, Hancock D, Sheridan C, Kumar M, Downward J (2013) Coordinate Direct Input of Both KRAS and IGF1 Receptor to Activation of PI3 kinase in KRAS-Mutant Lung Cancer. Cancer Discov 3: 548-563.
20. O'neil B, Goff L, Kauh J, Strosberg J, Bekaii-Saab T, Lee R, Kazi A, Moore D, Learoyd M, Lush R, Sebti S, Sullivan D (2011) Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 29: 2350-2356.
21. O'reilly K, Rojo F, She Q, Solit D, Mills G, Smith D, Lane H, Hofmann F, Ludwig D, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
22. Poulikakos P, Solit D (2011) Resistance to MEK inhibitors: should we co-target upstream? Sci Signal 4: pe16.
23. Renshaw J, Taylor K, Bishop R, Valenti M, Brandon ADH, Gowan S, Eccles S, Ruddle R, Johnson L, Raynaud F, Selfe J, Thway K, Pietsch T, Pearson A, Shipley J (2013) Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clin Cancer Res 19: 5940-5951.
24. Roberts P, Usary J, Darr D, Dillon P, Pfefferle A, Whittle M, Duncan J, Johnson S, Combest A, Jin J, Zamboni W, Johnson G, Perou C, Sharpless N (2012) Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res 18: 5290-5303.
25. Rothenberg M, Poplin E, Sandler A. (2007) Phase I dose-escalation study of the anti-IGF-IR recombinant human IgG1 monoclonal antibody (Mab) IMC-A12, administered every other week to patients with advanced solid tumors. American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer International Conference on Molecular Targets and Cancer TherapeuticsSan Francisco, CA, USA.
26. Rowinsky E, Youssoufian H, Tonra J, Solomon P, Burtrum D, Ludwig D (2007) IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor. Clin Cancer Res 13: 5549s.
27. Rusconi P, Caiola E, Broggini M (2012) RAS/RAF/MEK inhibitors in oncology. Curr Med Chem 19: 1164-1176.
28. Schöffski P, Adkins D, Blay J, Gil T, Elias A, Rutkowski P, Pennock G, Youssoufian H, Gelderblom H, Willey R, Grebennik D (2013) An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours. Eur J Cancer 49: 3219-3228.
29. Shelton J, Steelman L, White E, Mccubrey J (2004) Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 3: 372-379.
30. Slomiany M, Black L, Kibbey M, Tingler M, Day T, Rosenzweig S (2007) Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 248: 269-279.
31. Storer B (1989) Design and analysis of phase I clinical trials. Biometrics 45: 925-937.
32. Turke A, Song Y, Costa C, Cook R, Arteaga C, Asara J, Engelman J (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72: 3228-3237.
33. Villanueva J, Vultur A, Lee J, Somasundaram R, Fukunaga-Kalabis M, Cipolla A, Wubbenhorst B, Xu X, Gimotty P, Kee D, Santiago-Walker A, Letrero R, D'andrea K, Pushparajan A, Hayden J, Brown K, Laquerre S, Mcarthur G, Sosman J, Nathanson K et al. (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683-695.
34. Yanochko G, Eckhart W (2006) Type I insulin-like growth factor receptor over-expression induces proliferation and anti-apoptotic signaling in a three-dimensional culture model of breast epithelial cells. Breast Cancer Res 8: R18.
35. Yeh T, Marsh V, Bernat B, Ballard J, Colwell H, Evans R, Parry J, Smith D, Brandhuber B, Gross S, Marlow A, Hurley B, Lyssikatos J, Lee P, Winkler J, Koch K, Wallace E (2007) Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res 13: 1576-1583.
36. Zinn R, Gardner E, Marchionni L, Murphy S, Dobromilskaya I, Hann C, Rudin C (2013) ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer. Mol Cancer Ther 12: 1131-1139.